St. Jude Medical Inc. (NYSE:STJ)’s share price hit a new 52-week high on Tuesday . The stock traded as high as $82.18 and last traded at $82.08, with a volume of 675,142 shares trading hands. The stock had previously closed at $82.01.

Several brokerages recently weighed in on STJ. Zacks Investment Research raised shares of St. Jude Medical from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a research report on Friday, April 22nd. Piper Jaffray Cos. lowered shares of St. Jude Medical from an “overweight” rating to a “neutral” rating in a research note on Thursday, April 28th. BTIG Research lowered shares of St. Jude Medical from a “buy” rating to a “neutral” rating in a research note on Monday, April 18th. They noted that the move was a valuation call. Wedbush lowered shares of St. Jude Medical from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $70.00 to $84.00 in a research note on Friday, July 15th. Finally, Canaccord Genuity reiterated a “hold” rating on shares of St. Jude Medical in a research note on Wednesday, April 20th. Twenty-two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $75.93.

The stock has a market cap of $23.80 billion and a PE ratio of 35.90. The stock’s 50-day moving average price is $78.95 and its 200-day moving average price is $65.51.

St. Jude Medical (NYSE:STJ) last announced its quarterly earnings data on Wednesday, July 20th. The medical technology company reported $1.06 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.06. During the same period last year, the company earned $1.07 earnings per share. The firm earned $1.56 billion during the quarter, compared to analysts’ expectations of $1.55 billion. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, equities analysts expect that St. Jude Medical Inc. will post $4.06 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Thursday, June 30th will be paid a $0.31 dividend. The ex-dividend date of this dividend is Tuesday, June 28th. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.51%.

Several hedge funds have recently made changes to their positions in STJ. Advantus Capital Management Inc boosted its stake in shares of St. Jude Medical by 3.3% in the fourth quarter. Advantus Capital Management Inc now owns 27,189 shares of the medical technology company’s stock worth $1,679,000 after buying an additional 877 shares during the period. Atlantic Trust Group LLC boosted its stake in shares of St. Jude Medical by 1.1% in the fourth quarter. Atlantic Trust Group LLC now owns 27,627 shares of the medical technology company’s stock worth $1,707,000 after buying an additional 298 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in shares of St. Jude Medical by 35.2% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 23,626 shares of the medical technology company’s stock worth $1,459,000 after buying an additional 6,157 shares during the period. Schroder Investment Management Group boosted its stake in shares of St. Jude Medical by 127.2% in the fourth quarter. Schroder Investment Management Group now owns 3,103,759 shares of the medical technology company’s stock worth $191,720,000 after buying an additional 1,737,451 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management CO. LTD. boosted its stake in shares of St. Jude Medical by 6.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. now owns 37,377 shares of the medical technology company’s stock worth $2,309,000 after buying an additional 2,252 shares during the period.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.